Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E96A TMZ Treatment Study

ABSTRACT: Temozolomide (TMZ) induces DNA alkylation lesions repaired primarily through base excision repair. To characterize transcriptional responses to TMZ in the context of impaired APE1 endonuclease activity, RNA-seq was performed on Pa03C Cas9 and E96A mutant cell lines following treatment. Cells were treated with TMZ for 4 hours or 8 hours, along with untreated controls. This dataset captures genotype-specific and time-dependent transcriptional responses to alkylation stress in PDAC cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE311738 | GEO | 2026/02/04

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

MiRNA expression data from TMZ-resistant GBM cell line

Project description:Glioblastoma multiforme(GBM) is the most common and lethal malignant primary brain tumor. Temozolomide (TMZ) is a promising chemo-therapeutic agent to treat GBM. However, resistance to TMZ develops quickly with a high frequency. The mechanisms underlying GBM cells’ resistance to TMZ are not fully understood. Non-coding RNAs are aberrantly expressed in many cancers and are highly involved in their pathogenesis including drug-resistence. In order to systematically study the role of miRNAs in GBM cells' resistence to TMZ , we built gene expression profiles of TMZ-resistant cell line and TMZ-sensitive cell line using miRNA gene expression microarrays.

2020-07-04 | GSE100775 | GEO

LncRNA and mRNA expression data from TMZ-resistant cell line

Project description:Glioblastoma multiforme (GBM) is the most common and lethal malignant primary brain tumor. Temozolomide (TMZ) is a promising chemo-therapeutic agent to treat GBM. However, resistance to TMZ develops quickly with a high frequency. The mechanisms underlying GBM cells’ resistance to TMZ are not fully understood. Long non-coding RNAs (lncRNAs) are aberrantly expressed in many cancers and are highly involved in their pathogenesis including drug-resistence. In order to systematically study the role of lncRNAs in GBM cells' resistence to TMZ , we built gene expression profiles of TMZ-resistant cell line and TMZ-sensitive cell line using lncRNA and mRNA gene expression microarrays.

2020-07-03 | GSE100736 | GEO

LncRNA and mRNA expression data from TMZ-resistant cell line

Project description:The discovery of long non-coding RNAs (lncRNAs) has improved the understanding of development and progression in various cancer sub-types. However, the role of lncRNAs in temozolomide (TMZ) resistance in glioblastoma (GBM) remains largely undefined. In this present study, the differential expression of lncRNAs were identified between U87 and U87TR (TMZ-resistant) cells and to find potential therapeutic targets of GBM for improving the survival of patients.

2022-03-30 | GSE199689 | GEO

Glioblastoma tumorspheres treated with perphenazine (PER) and temozolomide (TMZ)

Project description:Glioblastoma (GBM), a primary malignant brain tumor, has a poor prognosis, even with standard treatments such as radiotherapy and chemotherapy. In this study, we explored the anticancer effects of the synergistic combination of perphenazine (PER), a dopamine receptor D2/3 (DRD2/3) antagonist, and temozolomide (TMZ), a standard treatment for GBM, in patient-derived human GBM tumorspheres (TSs).

2025-03-01 | GSE275875 | GEO

Glioblastoma tumorspheres treated with perphenazine (PER) and temozolomide (TMZ)

Project description:Glioblastoma tumorspheres treated with perphenazine (PER) and temozolomide (TMZ)

| PRJNA1153448 | ENA

NES_functional_survivin vs NES_mutated_survivin exposed or unexposed to temozolomide (TMZ)

Project description:NES_functional_survivin vs NES_mutated_survivin exposed or unexposed to temozolomide (TMZ)

| PRJNA645912 | ENA

Chapter 3 - Anna Tribe - BCL6 is a context-dependent mediator of the glioblastoma therapy response

Project description:Whole proteome analysis of LN18 cell treated with one of five DNA-damaging treatments (fractionated irradiation (IRM), temozolomide (TMZ), acute irradiation 24 hours (IRS 24h), acute irradiation 48 hours (IRS 48h) or doxorubicin (Dox)) +/- the BCL6 inhibitor FX1.

| MSV000090274 | MassIVE

Gene expression analysis of primary human myeloid precursor cells treated with O6-benzylguanine (6BG) and Temozolomide (TMZ)

Project description:For the comparison of 6BG/TMZ with control sample, the predominant annotation among the upregulated genes is M-bM-^@M-^XapoptosisM-bM-^@M-^Y. The majority of the downregulated genes is assigned to heat shock proteins and proteins which bind unfolded proteins. To look at early changes in gene expression, primary human myeloid precursor cells (40 x 10^6 per sample) derived from 3 pooled CD34+ products were treated for 18 hours with control (vehicle), 6BG, TMZ, or 6BG/TMZ and cell pellets flash frozen. Total RNA were isolated at Miltenyi Biotec (Cologne, Germany) and bioinformatics analysis of four microarray datasets was performed by their Bioinformatics Group. The direct comparisons were: 6BG/TMZ vs Control, TMZ vs 6BG, 6BG/TMZ vs 6BG, 6BG/TMZ vs TMZ. A two-dye competitive hybridization of mRNAs derived from differently treated human cells in comparison to a reference mRNA derived from cells which underwent a different treatment was conducted. After treatment with two different drugs or a combination of both drugs, respectively, RNA was extracted from the cells and hybridized against the corresponding reference mRNA. As microarray platform, the PIQORM-bM-^DM-" Cell Death Microarray with 494 probes was used.

2013-06-03 | E-GEOD-44122 | biostudies-arrayexpress

Transcriptome U87MG TMZ resistant

Project description:Differential transcriptome analysis between control cells (U87MG), TMZ-resistant cells with continuous TMZ treatment (U87MG R50) and TMZ-resistant cells with interrupted treatment (U87MG OFF R50).

2024-02-13 | GSE253458 | GEO

E96A baseline transcriptional changes

Project description:APE1/Ref-1 is the primary apurinic/apyrimidinic endonuclease in the base excision repair pathway. To define baseline transcriptional changes resulting from loss of APE1 endonuclease activity, RNA-seq was performed on Pa03C pancreatic ductal adenocarcinoma cell lines engineered to carry a homozygous E96A mutation and on matched Cas9 controls. Cells were cultured under untreated conditions. This dataset provides gene expression profiles associated with impaired APE1 endonuclease function in PDAC cells.

2026-02-04 | GSE311737 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data